相关实验视频
Updated: Jan 13, 2026

10:42
A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
Published on: February 27, 2019
9.8K
作为内蛋白配方中的辅助成分的短:一篇小小的评论
Dorian Migoń1, Zbigniew Jaremicz1, Wojciech Kamysz1
1Department of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, Hallera 107, 80-416 Gdańsk, Poland.
Pharmaceutics
|October 29, 2025
概括
短提供治疗性蛋白质配方的辅助剂的多功能功能,增强稳定性和克服配方挑战. 它们的定义结构使得改善药物产品的合理设计成为可能.
科学领域:
- 制药科学 制药科学
- 生物技术是生物技术.
- 药物运输 药物运输 药物运输
背景情况:
- 生物制药药物,特别是基于蛋白质的药物,由于结构复杂性和敏感性,面临着配方和稳定性挑战.
- 短是一种未充分利用的辅助剂类,具有可调节的物理化学特性.
研究的目的:
- 审查当前关于短作为体蛋白配方中辅助剂的知识.
- 突出其功能多功能性和合理设计的潜力.
主要方法:
- 对蛋白质配方中短的实验研究的文献综述.
- 对短的物理化学特性和功能作用的分析.
- 讨论系统选和计算建模方法.
主要成果:
- 短可以充当稳定剂,抗氧化剂,降粘度剂和冷保护剂/冷保护剂或充填剂.
- 它们的模块化架构允许精确调整诸如极性,电荷和结电位等属性.
- 短的有限化学空间有助于合理的识别和设计.
结论:
- 短体显示显著的承诺,作为亲肠道蛋白质配方的多功能辅助剂.
- 理性设计策略可以利用它们的特性来提高稳定性和功能.
- 对于先进的生物制药产品,需要进一步开发短作为辅助剂.
相关概念视频
Drug Delivery: Parenteral Route
1.5K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
1.5K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
146
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
146

